About  Us

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

About  Us

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

​Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.

​Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.

Disease  Indications

Solid Tumors (Various)

Breast Cancer

Liver Cancer

Myelodysplastic Syndrome

Leukemia

Bone Marrow Disorders

Regen BioPharma has multiple technologies targeting various types of cancer and disorders of the immune system.

Disease  Indications

Solid Tumors (Various)

Breast Cancer

Liver Cancer

Myelodysplastic Syndrome

Leukemia

Bone Marrow Disorders

Regen BioPharma has multiple technologies targeting various types of cancer and disorders of the immune system.

Our Team

Management Team 

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience.  

David R. Koos, PhD, DBA

Chairman & CEO

Scientific Advisory Board 

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Our Team

Management Team 

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience.  

David R. Koos, PhD, DBA

Chairman & CEO

Scientific Advisory Board 

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Intellectual Property –  Issued Patents

Patent Number
Patent Title
Date Granted
US-11,324,719-B2
Small molecule agonists and antagonists of NR2F6 activity in humans
2022-10-05
US-11,241,427-B2
Small molecule modulators of NR2F6 Activity
2022-02-08
US-11,141,471-B2
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
2021-10-12
US-11,090,332-B2
Antigen specific mRNA cellular cancer vaccines
2021-08-17
US-11,053,503-B2
Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition
2021-07-06
US-10,088,485-B2
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
2018-10-02
US-9,091,696-B2
Modulation of NR2F6 and methods and uses thereof
2015-07-28
US-8,389,708-B2
Method of cancer treatment using siRNA silencing
2013-03-05
US-8,263,571-B2
Gene silencing of the brother of the regulator of imprinted sites (BORIS)
2012-09-11

tCellVax

Solid tumors – tCellVax – IND #16928

tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6 (Solid Tumors).

tCellVax

Solid tumors – tCellVax – IND #16928

tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6 (Solid Tumors).

dCellVax

Breast Cancer – dCellVax – IND #16200

CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”

dCellVax

Breast Cancer – dCellVax – IND #16200

CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”

KimerApt

Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC

DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC

DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.

DuraCAR

Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.

DuraCAR

Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS

HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience. He has a deep knowledge of start up businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth.

Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally he has authored / co-authored numerous peer reviewed journal articles.

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience. He has a deep knowledge of start up businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth.

Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally he has authored / co-authored numerous peer reviewed journal articles.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executive Director and CEO of the American Society for Microbiology, effective January 4, 2016. Before leading the American Society for Cell Biology, Dr. Bertuzzi was a senior scientific executive at the National Institutes of Health where he served as Director of the Office of Science Policy, Planning, and Communications, and as a science policy advisor to the NIH Director. Dr. Bertuzzi received his Ph.D. in Molecular Biotechnology from Milan, Italy and his Master’s in Public Health from the Bloomberg School of Public Health at the Johns Hopkins University in Baltimore with a specialization in health policy. ​

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executive Director and CEO of the American Society for Microbiology, effective January 4, 2016. Before leading the American Society for Cell Biology, Dr. Bertuzzi was a senior scientific executive at the National Institutes of Health where he served as Director of the Office of Science Policy, Planning, and Communications, and as a science policy advisor to the NIH Director. Dr. Bertuzzi received his Ph.D. in Molecular Biotechnology from Milan, Italy and his Master’s in Public Health from the Bloomberg School of Public Health at the Johns Hopkins University in Baltimore with a specialization in health policy. ​

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executive Director and CEO of the American Society for Microbiology, effective January 4, 2016. Before leading the American Society for Cell Biology, Dr. Bertuzzi was a senior scientific executive at the National Institutes of Health where he served as Director of the Office of Science Policy, Planning, and Communications, and as a science policy advisor to the NIH Director. Dr. Bertuzzi received his Ph.D. in Molecular Biotechnology from Milan, Italy and his Master’s in Public Health from the Bloomberg School of Public Health at the Johns Hopkins University in Baltimore with a specialization in health policy. ​

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection. Inventor of dCellVax, over 5 million dollars in grant funding.

Amit Patel, MD, MSc

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center, and the Translational Neuro-Oncology Laboratories at Moores Cancer Center. Professor of Neurosciences at the UCSD School of Medicine.

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. He has led development of drugs which entered clinical trials, including development of Filibuvir. Granted the prestigious Pfizer Achievement Award. At Genelux Corp he established the cancer stem cell program.

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’) of the French National Institute of Health and Medical Research (INSERM). His 189 publications received an average citation of 83.34. Hinrich Gronemeyer contributed to pioneering work on nuclear receptors and their therapeutic intervention by design of small molecule ligands.

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids. He is an author on more than 200 publications.

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature). He has 40 granted patents listed in www.lens.org.

He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.

For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.